Design and Process Development Services
Between 2011 and 2016, the projected growth of biologics is estimated at $52B from $140B to $192B. It is predicted that by 2016, eight of the top 10 and 27 of the top 50 best-selling global drug products will require 2 – 8°C cold-chain storage and handling. More than 70% of biologics and 100% of vaccines are temperature-sensitive.
At Intelsius, we understand the costs involved in developing the next life-saving treatment or cure for the human or animals populations. Patient safety is our top priority too – that’s why we take your company, product and philosophy to heart in designing the most cost-effective, regulatory-compliant, temperature controlled solution for your payload.
With ATMOS™ (Analytical Thermal Modelling Software), a proprietary, predictive modelling software system designed by Intelsius, you could have a clear sense of direction for your temperature-controlled solutions in days.
ATMOS may save your company as much as 70% in packaging development time and costs. ATMOS requires significantly less time and energy than traditional environmental chamber testing.